Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 04:24 ET | Source: Karolinska Development AB (publ)

Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma

Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till extra bolagsstämma torsdagen den 8 januari 2026 kl. 10.00 hos Cirio...
December 02, 2025 04:24 ET | Source: Karolinska Development AB (publ)

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Thursday January 8,...
December 01, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development AB (publ) offentliggör företrädesemission om upp till cirka 203 MSEK, villkorat av bolagsstämmans efterföljande godkännande samt föreslår namnbyte till KDventures AB

EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM...
December 01, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
November 17, 2025 03:16 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data om fördelar av tidig behandling med golexanolon vid Parkinsons sjukdom

STOCKHOLM, 17 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterat data som visar varaktiga fördelar av tidig behandling med...
November 17, 2025 03:16 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

STOCKHOLM – November 17, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has published data in the scientific journal...
November 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Delårsrapport för januari – september 2025

STOCKHOLM – den 14 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – september 2025. Den fulla rapporten är tillgänglig på bolagets...
November 14, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Interim Report - January-September 2025

STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. “We...
November 04, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics får klartecken att starta den andra delen av en klinisk fas 2-studie i kronisk njursjukdom med anemi

STOCKHOLM, 4 november, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har fått regulatoriskt godkännande att inleda den andra delen av...
November 04, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the...